MediLink Therapeutics will present its next-generation TMALIN ("Tumor Microenvironment Activable LINker-payload”) platform and preclinical results of YL205, a novel antibody drug conjugate targeting NaPi2b, at the American Association for Cancer Research 2024 meeting (AACR 2024), which takes place April 5-10 in San Diego, United States. Presented studies are as follows:
2024-04-07
SUZHOU, CHINA, January 2nd, 2024 -- MediLink Therapeutics (“MediLink”), announced today that it has entered into a worldwide collaboration and license agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) on the development of a next-generation antibody-drug conjugate candidate YL211, targeting c-Mesenchymal epithelial transition factor (c-Met) against solid tumors.
2024-01-02
2022-04-12Learn more
2021-03-01Learn more
